Biopharmaceutical researcher and developer vTv Therapeutics has entered into a global licensing agreement with Reneo Pharmaceuticals. Reneo, based in San Diego, California, is a private biotechnology company that seeks medical applications for drugs developed by other companies. The agreement will allow Reneo to research, develop, and commercialize vTv’s peroxisome proliferator-activated receptor delta (PPAR-delta) program for undisclosed purposes. vTv is in the business of researching and developing orally-administered, small-molecule treatments for significant diseases. Administrations of one drug in the program, HPP593, have been correlated with lower concentrations of “bad” cholesterol in test animals and humans and a reduction in type 2 diabetes in various animals. No serious side effects have been noted. In exchange for handing off the program, vTv will receive an upfront payment that includes shares of common stock, with opportunities for future payments when milestones in development and commercialization are attained, and royalties from any sales of approved vTv products.